You are here



24 Jan 2011: Hain Lifescience has placed a new order of 25 Arrow instruments for delivery in Q1-2011[...]

24 Jan 2011: Hain Lifescience has placed a new order of 25 Arrow instruments for delivery in Q1-2011. "The new order confirms that instruments from our partners find their way out to the end user market; laboratories and hospitals", says CEO in NorDiag, Mårten Wigstøl. 

Hain Lifescience and NorDiag signed an OEM agreement in January 2010, and Hain placed its first order for 25 Arrow instruments medio March for delivery in Q2 last year. (See stock exchange release of March 23 2010). Hain is also purchasing reagents on a regular basis.
"We are pleased to see this new order from Hain. Our OEM-partners are vital for fast deployment of the Arrow instrument, and the order reflects that the demand for the instrument in the value chain are picking up", comments Wigstøl.
Hain Lifesciences currently have a range of assays, among others Tuberculosis, H-pylori and C-diff. The tuberculosis assay is officially recommended by World Health Organisation (WHO).
Contact: CEO Mårten Wigstøl               Phone. +47 911 65775
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and is the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The company has offices and laboratories in Stockholm, Sweden, in West Chester (PA), USA and in Vienna, Austria. The group has today 40 man-labour years. NorDiag is listed on Oslo Stock Exchange with ticker NORD.
For further information -

Read the Notice in Norwegian here